Disease · MONDO_0015265
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| L-CsA Treatment Plus SoC - SAF vs Standard of Care - SAF: deaths from any cause | 2 of 84 | 4 of 85 | 169 | NCT03656926 | Trial comparisons |
| L-CsA Treatment Plus SoC - SAF vs Standard of Care - SAF: serious adverse events | 46 of 84 | 44 of 85 | 169 | NCT03656926 | Trial comparisons |
| L-CsA treatment plus SoC (SAF) vs SoC alone (SAF): deaths from any cause | 6 of 32 | 3 of 30 | 62 | NCT03657342 | Trial comparisons |
| L-CsA treatment plus SoC (SAF) vs SoC alone (SAF): serious adverse events | 20 of 32 | 14 of 30 | 62 | NCT03657342 | Trial comparisons |
| Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: deaths from any cause | 0 of 20 | 0 of 3 | 23 | NCT01287078 | Trial comparisons |
| Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: serious adverse events | 5 of 20 | 0 of 3 | 23 | NCT01287078 | Trial comparisons |
| Liposomal Aerosol Cyclosporine vs Conventional Oral Immune Suppression: Number Of Participants With Chronic Rejection Who Met Primary Combined End-point | 2 of 11 | 5 of 10 | 21 | NCT01650545 | Trial comparisons |
| Liposomal Aerosol Cyclosporine vs Conventional Oral Immune Suppression: Overall Survival at 5 Years Follow-up | 5 of 11 | 0 of 10 | 21 | NCT01650545 | Trial comparisons |
| Liposomal Aerosol Cyclosporine vs Conventional Oral Immune Suppression: deaths from any cause | 6 of 11 | 10 of 10 | 21 | NCT01650545 | Trial comparisons |
| Liposomal Aerosol Cyclosporine vs Conventional Oral Immune Suppression: serious adverse events | 8 of 11 | 8 of 10 | 21 | NCT01650545 | Trial comparisons |
| Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: Stable or Progressive Disease at Baseline With Improvement of FEV1 | 4 of 16 | 0 of 2 | 18 | NCT01287078 | Trial comparisons |
| Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: Stable or Progressive Disease at Baseline With Greater Than 20% of Decline in FEV1 | 1 of 16 | 0 of 2 | 18 | NCT01287078 | Trial comparisons |
| Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: Disease Progression at Baseline With Stablization of FEV1 | 2 of 16 | 0 of 2 | 18 | NCT01287078 | Trial comparisons |
Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: Disease Stability at Baseline With Stablization in FEV1 and Greater Than 25% Decline in Systemic Immunosuppression | 3 of 16 | 0 of 2 | 18 | NCT01287078 | Trial comparisons |
Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: Stable Disease at Baseline With Stablization of FEV1 and no Change or Increase in Systemic Immunosuppresion | 4 of 16 | 2 of 2 | 18 | NCT01287078 | Trial comparisons |
| Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: Disease Progression at Baseline With Decline in FEV1 Greater Than 10% | 2 of 16 | 0 of 2 | 18 | NCT01287078 | Trial comparisons |
| Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS) | 9 of 16 | 0 of 2 | 18 | NCT01287078 | Trial comparisons |
| Inhaled Cyclosporine in HSCT Recipients vs Inhaled Cyclosporine in Lung Transplant Recipients: Overall Non-response to Treatment | 7 of 16 | 2 of 2 | 18 | NCT01287078 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015265/comparisons